Resection of liver metastases from colorectal mucinous adenocarcinoma: Is this a different disease? Results of a case-control study

Annals of Surgery

Volumn 260, Issue 5, 2014, Pages 878-885

  Viganò, Luca ^a,b   Russolillo, Nadia ^a   Ferrero, Alessandro ^a   De Rosa, Giovanni ^a   Ferreri, Erika ^a   Forchino, Fabio ^a   Sperti, Elisa ^a   Capussotti, Lorenzo ^a  

^a MAURIZIANO HOSPITAL   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Colorectal liver metastases; K ras mutation; Liver surgery; Mucinous colorectal cancer; Preoperative chemotherapy

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN;

ADULT; AGED; BONE METASTASIS; BRAIN METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CASE CONTROL STUDY; COLORECTAL CARCINOMA; COLORECTAL MUCINOUS ADENOCARCINOMA; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE FREE INTERVAL; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG SUBSTITUTION; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; HUMAN TISSUE; LIVER METASTASIS; LIVER RESECTION; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS RESECTION; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; REOPERATION; TREATMENT RESPONSE; ADENOCARCINOMA, MUCINOUS; ADJUVANT CHEMOTHERAPY; COLORECTAL TUMOR; LIVER NEOPLASMS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SECONDARY; SURVIVAL RATE; VERY ELDERLY;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; FEMALE; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE;

EID: 84926113371     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0000000000000981     Document Type: Conference Paper

References (44)

1. Viganò L, Ferrero A, Lo Tesoriere R, et al. Liver surgery for colorectal metastases: results after 10 years of follow-up. Long-termsurvivors, late recurrences, and prognostic role of morbidity. Ann Surg Oncol. 2008;15:2458-2464.
2. House MG, Ito H, Gonën M, et al. Survival after hepatic resection for metastatic colorectal cancer: Trends in outcomes for 1, 600 patients during two decades at a single institution. J Am Coll Surg. 2010;210:744-752.
3. de Haas RJ, Wicherts DA, Andreani P, et al. Impact of expanding criteria for resectability of colorectal metastases on short- And long-term outcomes after hepatic resection. Ann Surg. 2011;253:1069-1079.
4. Aloia TA, Vauthey JN. Management of colorectal liver metastases: Past, present, and future. Updates Surg. 2011;63:1-3.
5. Simmonds PC, Primrose JN, Colquitt JL, et al. Surgical resection of hepatic metastases from colorectal cancer: A systematic review of published studies. Br J Cancer. 2006;94:982-999.
6. Viganò L, Capussotti L, De Rosa G, et al. Liver resection for colorectal metastases after chemotherapy: Impact of chemotherapy-related liver injuries, pathological tumor response, and micrometastases on long-term survival. Ann Surg. 2013;258:731-740.
7. Ribero D, Viganò L, Amisano M, et al. Prognostic factors after resection of colorectal liver metastases: From morphology to biology. Future Oncol. 2013;9:45-57.
8. Gregoire E, Hoti E, Gorden DL, et al. Utility or futility of prognostic scoring systems for colorectal liver metastases in an era of advanced multimodal therapy. Eur J Surg Oncol. 2010;36:568-574.
9. Cardona K, Mastrodomenico P, D'Amico F, et al. Detailed pathologic characteristics of the primary colorectal tumor independently predict outcome after hepatectomy for metastases. Ann Surg Oncol. 2013;20:148-154.
10. Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Française de Chirurgie. Cancer. 1996;77:1254-1262.
11. Hamilton SR, Aaltonen LA. Pathology and genetics: Tumours of the digestive system. In: Hamilton SR, Aaltonen LA, eds. World Health Organization Classification of Tumours. 3rd ed. Lyon, France: IARC; 2000: 103-143.
12. Levin KE, Dozois RR. Epidemiology of large bowel cancer. World J Surg. 1991;15:562-567.
13. Nozoe T, Anai H, Nasu S, et al. Clinicopathological characteristics of mucinous carcinoma of the colon and rectum. J Surg Oncol. 2000;75:103-107.
14. Kanemitsu Y, Kato T, Hirai T, et al. Survival after curative resection for mucinous adenocarcinoma of the colorectum. Dis Colon Rectum. 2003;46:160-167.
15. Negri FV, Wotherspoon A, Cunningham D, et al. Mucinous histology predicts for reduced fluorouracil responsiveness and survival in advanced colorectal cancer. Ann Oncol. 2005;16:1305-1310.
16. Catalano V, Loupakis F, Graziano F, et al. Prognosis of mucinous histology for patients with radically resected stage II and III colon cancer. Ann Oncol. 2012;23:135-141.
17. Kim SH, Shin SJ, Lee KY, et al. Prognostic value of mucinous histology depends on microsatellite instability status in patients with stage III colon cancer treated with adjuvant FOLFOX chemotherapy: A retrospective cohort study. Ann Surg Oncol. 2013;20:3407-3413.
18. Nitsche U, Zimmermann A, Späth C, et al. Mucinous and signet-ring cell colorectal cancers differ from classical adenocarcinomas in tumor biology and prognosis. Ann Surg. 2013;258:775-778.
19. Verhulst J, Ferdinande L, Demetter P, et al. Mucinous subtype as prognostic factor in colorectal cancer: A systematic review and meta-analysis. J Clin Pathol. 2012;65:381-388.
20. Chen JX, Tang XD, Xiang DB, et al. TNM stages and prognostic features of colorectal mucinous adenocarcinomas: A meta-analysis. Asian Pac J Cancer Prev. 2012;13:3427-3430.
21. Catalano V, Loupakis F, Graziano F, et al. Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- And/or irinotecan-based chemotherapy. Br J Cancer. 2009;100:881-887.
22. Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: Analysis of 1001 consecutive cases. Ann Surg. 1999;230:309-318.
23. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): A randomised controlled trial. Lancet Oncol. 2013;14:1208-1215.
24. Vigano L, Langella S, Ferrero A, et al. Colorectal cancer with synchronous resectable liver metastases: monocentric management in a hepatobiliary referral center improves survival outcomes. Ann Surg Oncol. 2013;20:938- 945.
25. Vigano' L, Russolillo N, Ferrero A, et al. Evolution of long-term outcome of liver resection for colorectal metastases: Analysis of actual 5-year survival rates over two decades. Ann Surg Oncol. 2012;19:2035-2044.
26. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: A new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205-213.
27. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
28. Sugarbaker PH. Mucinous colorectal carcinoma. J Surg Oncol. 2001;77:282- 283.
29. Ogino S, Brahmandam M, Cantor M, et al. Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component. Mod Pathol. 2006;19:59-68.
30. Song GA, Deng G, Bell I, et al. Mucinous carcinomas of the colorectum have distinct molecular genetic characteristics. Int J Oncol. 2005;26: 745-750.
31. Tanaka H, Deng G, Matsuzaki K, et al. BRAF mutation, CpG island methylator phenotype and microsatellite instability occur more frequently and concordantly in mucinous than non-mucinous colorectal cancer. Int J Cancer. 2006; 118:2765-2771.
32. Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology. 2007;50: 113-130.
33. Hanski C. Is mucinous carcinoma of the colorectum a distinct genetic entity? Br J Cancer. 1995;72:1350-1356.
34. Chew MH, Yeo SA, Ng ZP, et al. Critical analysis of mucin and signet ring cell as prognostic factors in an Asian population of 2, 764 sporadic colorectalcancers. Int J Colorectal Dis. 2010;25:1221-1229.
35. Hyngstrom JR, Hu CY, Xing Y, et al. Clinicopathology and outcomes for mucinous and signet ring colorectal adenocarcinoma: Analysis from the National Cancer Data Base. Ann Surg Oncol. 2012;19:2814-2821.
36. Kang H, O'Connell JB, Maggard MA, et al. A 10-year outcomes evaluation of mucinous and signet-ring cell carcinoma of the colon and rectum. Dis Colon Rectum. 2005;48:1161-1168.
37. Yamaguchi T, Taniguchi H, Fujita S, et al. Clinicopathological characteristics and prognostic factors of advanced colorectal mucinous adenocarcinoma. Histopathology. 2012;61:162-169.
38. Numata M, Shiozawa M, Watanabe T, et al. The clinicopathological features of colorectal muci nous adenocarcinoma and a therapeutic strategy for the disease. World J Surg Oncol. 2012;15:100-109.
39. Consorti F, Lorenzotti A, Midiri G, et al. Prognostic significance of mucinous carcinoma of colon and rectum: A prospective case-control study. J Surg Oncol. 2000;73:70-74.
40. Papadopoulos VN, Michalopoulos A, Netta S, et al. Prognostic significance of mucinous component in colorectal carcinoma. Tech Coloproctol. 2004;8: 123-125.
41. Farhat MH, Barada KA, Tawil AN, et al. Effect of mucin production on survival in colorectal cancer: A case-control study. World J Gastroenterol. 2008;14:6981-6985.
42. Petrowsky H, Gonen M, Jarnagin W, et al. Second liver resections are safe and effective treatment for recurrent hepatic metastases from colorectal cancer: A bi-institutional analysis. Ann Surg. 2002;235:863-871.
43. Wicherts DA, deHaas RJ, Salloum C, et al. Repeat hepatectomy for recurrent colorectal metastases. Br J Surg. 2013;100:808-818.
44. Viganò L, Capussotti L, Lapointe R, et al. Early recurrence after liver resection for colorectal metastases: risk factors, prognosis, and treatment. A Liver Met Survey-based study of 6, 025 patients. Ann Surg Oncol. 2014;21:1276-1286.